FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research note published on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th.

FibroGen Stock Performance

FGEN opened at $0.36 on Friday. The stock’s fifty day simple moving average is $0.36 and its 200 day simple moving average is $0.61. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.93. The stock has a market cap of $36.77 million, a PE ratio of -0.30 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the prior year, the business posted ($0.52) EPS. Equities analysts forecast that FibroGen will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On FibroGen

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC increased its stake in FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after acquiring an additional 860,854 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of FibroGen by 139.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after purchasing an additional 769,586 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of FibroGen during the 3rd quarter worth $307,000. XTX Topco Ltd acquired a new position in shares of FibroGen during the 2nd quarter worth $424,000. Finally, Cubist Systematic Strategies LLC lifted its position in shares of FibroGen by 3,906.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 280,161 shares during the last quarter. 72.71% of the stock is currently owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.